Universal Anti-Viral Vaccine for Healthy Elderly Adults (ALLOPRIME)
Safety and Efficacy of ALLOSTIM® Universal Anti-Viral Immunodulatory Vaccine for Healthy Elderly Adults
Sponsor: Mirror Biologics, Inc.
This PHASE1/PHASE2 trial investigates ARDS, Human and COVID-19 Respiratory Infection and is currently completed. Mirror Biologics, Inc. leads this study, which shows 14 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
14 versions recorded-
Feb 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
▶ Show 9 earlier versions
-
Sep 2022 — May 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2021 — Apr 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Feb 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Aug 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Mirror Biologics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .